dc.contributor
Universitat de Barcelona. Facultat de Medicina i Ciències de la Salut
dc.contributor.author
Martinez Verbo, Laura
dc.date.accessioned
2025-03-19T08:22:39Z
dc.date.available
2025-03-19T08:22:39Z
dc.date.issued
2024-12-20
dc.identifier.uri
http://hdl.handle.net/10803/694028
dc.description
Tesi realitzada a l'Institut de Recerca contra la Leucèmia Josep Carreras
ca
dc.description.abstract
[eng] HYPOTHESIS:
Epigenetics influence cancer and recently epigenetic plasticity has been included as a new hallmark of cancer described in the latest published work of Hanahan113. Growing scientific evidence has pointed out the importance of epigenetic regulation in immunology106 and the important role of immune checkpoint regulation in tumor recognition and clearance. As observed in clinical settings, therapeutic strategies for solid and hematological tumors often build upon each other’s successes. Solid tumors have shown greater therapeutic success in the context of immune checkpoint targeting. This is mainly due to solid tumors' well-defined TME, facilitating more effective inhibition of pathways regulating immune cell activity. Based on this, we hypothesized that an epigenetically regulated gene plays a key role in immune checkpoint regulation, which could be critical in hematological malignancies. Despite the less distinct TME in these cancers, the mechanisms of immune cell recognition remain significant. With this foundation, the following objectives were established for this thesis project.
OBJECTIVES:
We have decided to divide this thesis project into three different objectives.
The overarching objective of this thesis was to study the regulation of PVR and its relation to cytotoxic activation in the context of MM. The specific objectives of this thesis are:
- Objective I: To characterize PVR’s epigenetic regulation and expression in multiple myeloma.
- Objective II: To evaluate the role of PVR in cytotoxic cell function and its impact on immunotherapy.
- Objective III: To study the effect of PVR expression alteration and its relationship with other immune checkpoint markers.
ca
dc.format.extent
150 p.
ca
dc.publisher
Universitat de Barcelona
dc.rights.license
ADVERTIMENT. Tots els drets reservats. L'accés als continguts d'aquesta tesi doctoral i la seva utilització ha de respectar els drets de la persona autora. Pot ser utilitzada per a consulta o estudi personal, així com en activitats o materials d'investigació i docència en els termes establerts a l'art. 32 del Text Refós de la Llei de Propietat Intel·lectual (RDL 1/1996). Per altres utilitzacions es requereix l'autorització prèvia i expressa de la persona autora. En qualsevol cas, en la utilització dels seus continguts caldrà indicar de forma clara el nom i cognoms de la persona autora i el títol de la tesi doctoral. No s'autoritza la seva reproducció o altres formes d'explotació efectuades amb finalitats de lucre ni la seva comunicació pública des d'un lloc aliè al servei TDX. Tampoc s'autoritza la presentació del seu contingut en una finestra o marc aliè a TDX (framing). Aquesta reserva de drets afecta tant als continguts de la tesi com als seus resums i índexs.
ca
dc.source
TDX (Tesis Doctorals en Xarxa)
dc.subject
Immunoteràpia
ca
dc.subject
Inmunoterapia
ca
dc.subject
Immunotheraphy
ca
dc.subject
Epigenètica
ca
dc.subject
Epigenética
ca
dc.subject
Epigenetics
ca
dc.subject
Immunologia
ca
dc.subject
Inmunología
ca
dc.subject
Mieloma múltiple
ca
dc.subject
Multiple myeloma
ca
dc.subject.other
Ciències de la Salut
ca
dc.title
Epic Battles in Myeloma: Deciphering the Role of PVR in the Fight Between Tumors and Cytotoxic Cells
ca
dc.type
info:eu-repo/semantics/doctoralThesis
dc.type
info:eu-repo/semantics/publishedVersion
dc.contributor.director
Esteller, Manel
dc.contributor.director
Ferrer Aguilar, Gerardo
dc.contributor.tutor
Esteller, Manel
dc.rights.accessLevel
info:eu-repo/semantics/openAccess
dc.description.degree
Biomedicina
ca
